eglumetad

LY-354740 is the active isomer, LY-366563 is the inactive isomer, and LY 314582 is the racemate; structure given in first source

Also Known As:

(+)-(1S,2S,5R,6S)-2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; 2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; LY 314582; LY 354740; LY 366563; LY-314582; LY-354740; LY-366563; LY314582; LY354740; LY366563

Networked: 38 relevant articles (6 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schoepp, Darryle D: 4 articles (06/2008 - 02/2006)
2.	Pilc, A: 3 articles (09/2015 - 01/2000)
3.	Danysz, Wojciech: 3 articles (11/2009 - 09/2005)
4.	Monn, James A: 2 articles (11/2014 - 04/2007)
5.	Morè, Lorenzo: 2 articles (11/2009 - 02/2009)
6.	Pietraszek, Małgorzata: 2 articles (11/2009 - 02/2009)
7.	Schlumberger, Chantal: 2 articles (11/2009 - 02/2009)
8.	Johnson, Bryan G: 2 articles (04/2007 - 02/2006)
9.	McKinzie, David L: 2 articles (04/2007 - 02/2006)
10.	Rorick-Kehn, Linda M: 2 articles (04/2007 - 02/2006)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2011 - "Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclinical animal models of anxiety and schizophrenia. " 02/01/2009 - "In conclusion, LY354740 was effective in models for anxiety and positive symptoms of schizophrenia but not in models for sensorimotor gating and cognitive impairment." 11/01/2014 - "These data strengthen the validity of PRS mice as a model of schizophrenia, and show for the first time a pharmacodynamic difference between LY379268 and LY354740 which might be taken into account in an attempt to explain the differential effect of the two drugs across mouse models. " 11/25/2009 - "In conclusion, in selected rodent models for positive schizophrenia symptoms, ADX47273 showed better efficacy than LY354740." 02/01/2009 - "Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition."
2.	Psychotic Disorders (Schizoaffective Disorder) 08/01/2006 - "LY354740 is a potent and selective mGlu2/3 receptor agonist with activity in models of psychiatric disorders (anxiety, psychosis), and early clinical studies in anxiety patients. " 02/01/2006 - "Numerous studies have indicated that selective agonists of group II metabotropic glutamate (mGlu) receptors, such as LY354740 [(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate] and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], may be useful in the treatment of many psychiatric disorders, including psychosis, anxiety, and drug withdrawal. " 02/01/2006 - "Furthermore, we compare the oral efficacy of the mGlu2/3 receptor agonist LY354740 and its prodrug LY544344 [(1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride] in rodent models of psychosis and anxiety. " 08/01/2022 - "After induction of parkinsonism with MPTP, marmosets entered 3 streams of experiments, in which the following treatments were administered, in combination with l-3,4-dihydroxyphenylalanine (L-DOPA), after which dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism were rated: 1. vehicle/vehicle, LY354740 (mGlu2/3 orthosteric agonist)/vehicle, LY354740/LY341495 1 mg/kg and LY354740/LY341495 3 mg/kg; 2. vehicle/vehicle, LY487379 (mGlu2 positive allosteric modulator)/vehicle, LY487379/LY341495 1 mg/kg and LY487379/LY341495 3 mg/kg; 3. vehicle/vehicle, EMD-281,014 (5-HT2A antagonist)/vehicle, EMD-281,014/LY341495 1 mg/kg and EMD-281,014/LY341495 3 mg/kg. Each of LY354740, LY487379 and EMD-281,014 reduced the severity of L-DOPA-induced dyskinesia, by 55%, 39% and 40%, respectively (all p < 0.001), as well as the severity of PLBs, by 48%, 36% and 41%, respectively (all p < 0.001). "
3.	Mental Disorders (Mental Disorder) 08/01/2006 - "LY354740 is a potent and selective mGlu2/3 receptor agonist with activity in models of psychiatric disorders (anxiety, psychosis), and early clinical studies in anxiety patients. " 01/28/2009 - "The synergistic action of BINA on LY354740's effects on sleep pattern implies that positive modulators would tune the endogenous glutamate tone suggesting potential benefit in the treatment of psychiatric disorders, in which REM sleep overdrive is manifested." 04/01/2007 - "These characteristics suggest LY404039 modulates glutamatergic activity in limbic and forebrain areas relevant to psychiatric disorders; and that, similar to LY354740, it works through a mechanism that may be devoid of negative side effects associated with current antipsychotics and anxiolytics. " 02/01/2006 - "Numerous studies have indicated that selective agonists of group II metabotropic glutamate (mGlu) receptors, such as LY354740 [(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate] and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], may be useful in the treatment of many psychiatric disorders, including psychosis, anxiety, and drug withdrawal. "
4.	Cognitive Dysfunction 06/01/2004 - "Using a combination of mGlu2 receptor knockout mice and the group II agonist LY354740, we show that activation of mGlu2 receptors produces a cognitive impairment, i.e. " 02/01/2009 - "In conclusion, LY354740 was effective in models for anxiety and positive symptoms of schizophrenia but not in models for sensorimotor gating and cognitive impairment." 02/01/2009 - "The aim of this study was to evaluate further the effect of the mGluR2/3 agonist, LY354740 [(+)-2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylate monohydrate] in animal models relevant to both psychotic and cognitive impairment in schizophrenia. "
5.	Ischemia 01/01/1999 - "LY354740 and LY379268 were protective against transient global ischemia in gerbils when dosed intraperitoneally. " 07/13/2015 - "In the present study, reduced mechanical thresholds for hindpaw-withdrawal reflex were found in mice after transient hindpaw ischemia, which was produced by a high pressure applied around the hindpaw for 30 min. The reduction in the threshold was blocked by spinal application of LY354740, a specific agonist of group II metabotropic glutamate receptors. "

Related Drugs and Biologics

1.	LY 379268
2.	Hexanes
3.	Glutamic Acid (Glutamate)
4.	Prodrugs
5.	Levodopa (L Dopa)
6.	2- ((2'- amino)propionyl)aminobicyclo(3.1.0)hexane- 2,6- dicarboxylic acid
7.	Serotonin 5-HT2 Receptor Antagonists
8.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
9.	Acids
10.	N- (4- (2- methoxyphenoxy)phenyl)- N- (2,2,2- trifluoroethylsulfonyl)pyrid- 3- ylmethylamine

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Therapeutics